Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C1S | P09871 | 1/20 | 0.32 |
| ▸ | NAT1 | P18440 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
| ▸ | LIPC | P11150 | 1/20 | 0.30 |
| ▸ | IDH2 | P48735 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 2/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3649326 | 0.89 | HTR6 (0.39) | HTR6HTR2AHTR2CHTR7 | |
| SCHEMBL4125901 | 0.89 | NAMPT (0.35) | LIPGLIPCIDH2 | |
| SCHEMBL4028253 | 0.88 | F2 (0.31) | — | |
| SCHEMBL3654891 | 0.87 | ATM (0.34) | C1SLIPGGRM4LIPCIDH2 | |
| SCHEMBL4028261 | 0.87 | — | — | |
| SCHEMBL4117657 | 0.87 | GPBAR1 (0.33) | LIPGLIPCIDH2 | |
| SCHEMBL4125865 | 0.86 | LIMK2 (0.33) | LIPGIDH2 | |
| SCHEMBL4120645 | 0.86 | NFE2L2 (0.41) | — | |
| SCHEMBL4117741 | 0.85 | LIPG (0.31) | LIPGLIPCIDH2 | |
| SCHEMBL3782033 | 0.85 | NAMPT (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | C1S 1997/4885NAT1 2102/4885LIPG 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.